Piper Sandler's downgrade of Caleres from Overweight to Neutral and the lowering of the price target from $35 to $25 indicates a less optimistic outlook for the stock. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating and price target.